Acadia Pharmaceuticals' Rebranding and AI Integration
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand, expansion into rare disease marketing, and the role of AI in its strategy.
Neurological biotech Acadia Pharmaceuticals has introduced a new brand identity as it expands into the rare disease space, with AI playing a key role in its marketing approach.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's rebrand, rare disease expansion, and AI integration throughout commercialization and marketing.
- Adams shares her insights on the benefits and challenges of marketing as a smaller biotech.
This interview has been edited for length and clarity.
Author's summary: Acadia Pharmaceuticals rebrands and integrates AI.